RespireRx Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0011
- Today's High:
- $0.0013
- Open Price:
- $0.0012
- 52W Low:
- $0.001
- 52W High:
- $0.01
- Prev. Close:
- $0.0011
- Volume:
- 1805200
Company Statistics
- Market Cap.:
- $358447
- Book Value:
- -0.058
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -836.89%
- Return on Equity TTM:
- 0%
Company Profile
RespireRx Pharmaceuticals Inc had its IPO on under the ticker symbol RSPI.
The company operates in the Healthcare sector and Biotechnology industry. RespireRx Pharmaceuticals Inc has a staff strength of 2 employees.
Stock update
Shares of RespireRx Pharmaceuticals Inc opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0, and closed at $0.
This is a +18.18% increase from the previous day's closing price.
A total volume of 1,805,200 shares were traded at the close of the day’s session.
In the last one week, shares of RespireRx Pharmaceuticals Inc have increased by +8.33%.
RespireRx Pharmaceuticals Inc's Key Ratios
RespireRx Pharmaceuticals Inc has a market cap of $358447, indicating a price to book ratio of 0 and a price to sales ratio of 1051.0359.
In the last 12-months RespireRx Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures RespireRx Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, RespireRx Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -836.89% with a return of equity of 0%.
In Q2, RespireRx Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
RespireRx Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.03 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into RespireRx Pharmaceuticals Inc’s profitability.
RespireRx Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.7761. Its price to sales ratio in the trailing 12-months stood at 1051.0359.
RespireRx Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $141276.00
- Total Liabilities
- $12.21 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
RespireRx Pharmaceuticals Inc ended 2024 with $141276.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $141276.00 while shareholder equity stood at $-12142352.00.
RespireRx Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $12.21 million in other current liabilities, 220729.00 in common stock, $-177168949.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7321.00 and cash and short-term investments were $7321.00. The company’s total short-term debt was $2,873,478 while long-term debt stood at $0.
RespireRx Pharmaceuticals Inc’s total current assets stands at $141276.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, RespireRx Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, RespireRx Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0
- 52-Week High
- $0.01
- 52-Week Low
- $0.001
- Analyst Target Price
- $
RespireRx Pharmaceuticals Inc stock is currently trading at $0 per share. It touched a 52-week high of $0.01 and a 52-week low of $0.01. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 1.47 indicating a short percent outstanding of 0%.
Around 1543.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About RespireRx Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company’s lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.